Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Advanced Gastric Cancer
Interventions: Procedure: laparoscopy assisted distal gastrectomy; Procedure: open distal gastrectomy
Sponsor: National Cancer Center, Korea
Not yet recruiting - verified March 2010
Conditions: Advanced Gastric Cancer; Gastro-esophageal Junction Cancer
Interventions: Drug: AUY922; Drug: Docetaxel or Irinotecan
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Condition: Gastric Cancer
Interventions: Drug: ARQ 197; Drug: Oxaliplatin, capecitabine or irinotecan
Sponsor: ArQule
Withdrawn - verified February 2010
Conditions: Pregnancy; Helicobacter Pylori Infection; Iron-Deficiency Anemia
Intervention:
Sponsor: E-DA Hospital
Recruiting - verified February 2010
Condition: Gastric Cancer
Interventions: Drug: olaparib; Drug: paclitaxel; Drug: Placebo
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Gastric Cancer
Intervention: Device: Naso-Gastric/Jejunal Tube
Sponsor: Catholic University, Italy
Recruiting - verified January 2010
Condition: Tumor
Intervention:
Sponsor: National Taiwan University Hospital
Completed - verified March 2010
Conditions: Squamous Cell Carcinoma; Adenocarcinoma; Esophageal Cancer; Gastro-esophageal Junction Cancer
Interventions: Drug: carboplatin; Drug: Paclitaxel; Drug: Panitumumab; Radiation: 3-D conformal radiation
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified July 2009
Conditions: Ovarian Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Cancer of Head and Neck
Intervention: Drug: LY2523355
Sponsor: Eli Lilly and Company
Not yet recruiting - verified March 2010
Conditions: Stomach Neoplasm; Laparoscopy; Gastrectomy
Interventions: Procedure: Laparoscopy-assisted gastrectomy; Procedure: Open gastrectomy
Sponsor: Southwest Hospital, China
Recruiting - verified February 2010
Condition: Solid Tumors
Interventions: Drug: MK1775; Drug: Comparator: MK1775 in combination with 5-FU; Drug: Comparator: MK1775 in combination with 5-FU/CDDP
Sponsor: Merck
Recruiting - verified February 2010
Condition: Gastric Cancer
Interventions: Drug: trastuzumab; Drug: fluorouracil; Drug: cisplatin; Drug: capecitabine
Sponsors: Hoffmann-La Roche; Chugai Pharmaceutical
Active, not recruiting - verified February 2010
Condition: Gastro-Intestinal Cancer
Interventions: Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan; Drug: Brivanib; Drug: Brivanib; Drug: Brivanib
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Stomach Neoplasms
Intervention: Drug: Ixabepilone
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: Hedgehog antagonist GDC-0449; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: New York Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoid Syndrome
Intervention: Drug: BIM 23A760
Sponsor: Ipsen
Recruiting - verified February 2010
Condition: Thrombocytopenia
Interventions: Drug: Eltrombopag; Drug: Placebo
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Condition: Colorectal Cancer
Intervention: Biological: Adaptive autologous cell immunotherapy
Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting - verified September 2009
Conditions: Stomach Cancer; Colon Cancer; Thyroid Cancer; Breast Cancer
Intervention: Behavioral: Brochure of Secondary Cancer Screening
Sponsor: National Cancer Center, Korea
Active, not recruiting - verified September 2009
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: capecitabine; Drug: docetaxel; Drug: fluorouracil; Drug: oxaliplatin
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Duodenal Obstruction; Gastric Outlet Obstruction
Intervention: Device: EVOLUTION® Duodenal Stent
Sponsor: Cook
Recruiting - verified March 2010
Conditions: Gastric Cancer; Adenocarcinoma
Interventions: Biological: IMC-1121B; Other: Placebo; Other: Best Supportive Care
Sponsor: ImClone LLC
Recruiting - verified March 2010
Condition: Esophageal Cancer
Intervention: Procedure: esophagectomy with extended two-field lymphadenectomy
Sponsor: University Hospital, Lille
Recruiting - verified July 2009
Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified February 2010
Conditions: Stomach Neoplasms; Esophageal Neoplasms
Interventions: Drug: BMS-833923; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified December 2009
Conditions: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Gastric Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: capecitabine [Xeloda]; Drug: cisplatin; Drug: Placebo
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Conditions: Stomach Neoplasms; Advanced Gastric Cancer
Interventions: Drug: axitinib; Drug: capecitabine; Drug: cisplatin
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: 177Lu-J591; Drug: Ketoconazole; Drug: Hydrocortisone; Drug: 111In-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Condition: Non Functioning Entero-Pancreatic Endocrine Tumour
Intervention: Drug: lanreotide
Sponsor: Ipsen
Enrolling by invitation - verified February 2010
Condition: Gastric Cancer
Intervention: Drug: DOX: Docetaxel, oxaliplatin, Capecitabine
Sponsors: Spanish Cooperative Group for Gastrointestinal Tumour Therapy; Sanofi-Aventis; Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Esophagogastric Junction Adenocarcinoma; Gastric Cancer; Esophageal Cancer
Interventions: Drug: Capecitabine; Drug: Epirubicin; Drug: AMG 102; Drug: Cisplatin
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Healthy
Interventions: Drug: Nilotinib Hydrochloride; Dietary Supplement: calcium carbonate
Sponsors: University of Pittsburgh; Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Healthy
Interventions: Drug: Imatinib mesylate; Dietary Supplement: calcium carbonate
Sponsors: University of Pittsburgh; Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Acute Graft Versus Host Disease
Intervention: Drug: Etanercept (Enbrel)
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
Conditions: ErbB2 (HER2) Amplified Gastric; Esophageal; or Gastro-esophageal Junction Adenocarcinoma That is Unresectable Due to Locally Advanced Metastatic, or Locally Recurrent Disease.
Intervention: Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Chronic Myelogenous Leukemia - Chronic Phase
Intervention: Drug: Nilotinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Stomach Neoplasms
Interventions: Drug: 5-fluorouracil; Drug: cisplatin; Drug: sunitinib malate
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Stomach Neoplasms
Interventions: Drug: capecitabine; Drug: oxaliplatin; Drug: sunitinib malate; Drug: capecitabine; Drug: cisplatin; Drug: sunitinib malate
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Stomach Neoplasms
Interventions: Drug: Cisplatin; Drug: S-1; Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Gastric Cancer
Interventions: Procedure: laparoscopy assisted distal gastrectomy; Procedure: Open distal gastrectomy
Sponsor: National Cancer Center, Korea
Recruiting - verified March 2010
Conditions: Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer
Intervention: Drug: Docetaxel plus lonafarnib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Conditions: Gastric Cancer; Precancerous Condition
Intervention: Biological: cetuximab
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Suspended - verified March 2010
Condition: Advanced Malignancies
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Gastric Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: Standard chemotherapy
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Conditions: Esophageal Neoplasms; Stomach Neoplasms; Neoplasm Metastasis
Intervention: Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Sponsors: Duke University; Hoffmann-La Roche; Sanofi-Aventis; Genentech
Recruiting - verified March 2010
Conditions: Adenocarcinoma of Stomach; Barrett Esophagus
Intervention: Drug: Sunitinib-Malate
Sponsors: Johannes Gutenberg University Mainz; Pfizer
Completed - verified March 2010
Conditions: Gastric Cancer; Pancreatic Cancer; Cervical Cancer; Vulvar Cancer; Endometrial Cancer; Anal Cancer
Interventions: Behavioral: Interview; Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; Merck
Recruiting - verified March 2010
Condition: Stomach Cancer
Intervention: Drug: Vinflunine
Sponsor: Bristol-Myers Squibb
Terminated - verified December 2007
Condition: Endocrine Tumors
Interventions: Drug: lanreotide (Autogel formulation); Other: Placebo
Sponsor: Ipsen
Recruiting - verified March 2010
Condition: Chronic Diseases
Intervention:
Sponsor: National Cancer Institute (NCI)
Completed - verified January 2010
Condition: Pancreatic Neoplasms
Intervention: Procedure: Celiac Plexus Neurolysis
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 2010
Condition: Esophageal Neoplasms
Intervention: Drug: Capecitabine (Xeloda)
Sponsors: Dartmouth-Hitchcock Medical Center; Sanofi-Aventis; Hoffmann-La Roche
Active, not recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: isolated perfusion; Drug: melphalan
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditions: Cancer; Metastases
Intervention: Drug: panHer
Sponsor: Bristol-Myers Squibb
Completed - verified October 2008
Conditions: Esophageal Cancer; Gastric Cancer
Interventions: Drug: capecitabine; Drug: irinotecan hydrochloride; Drug: oxaliplatin
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified March 2010
Conditions: Colorectal Cancer; Quality of Life
Interventions: Biological: cetuximab; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; Australasian Gastro-Intestinal Trials Group
Completed - verified March 2010
Condition: Cancer
Intervention: Drug: forodesine hydrochloride
Sponsor: BioCryst Pharmaceuticals
Completed - verified July 2004
Condition: Cancer
Interventions: Drug: docetaxel; Drug: thalidomide
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Conditions: Esophageal Cancer; Gastric Cancer
Interventions: Drug: irinotecan hydrochloride; Drug: paclitaxel
Sponsors: University of California, Los Angeles; National Cancer Institute (NCI)
Completed - verified February 2010
Condition: Cancer
Intervention: Drug: entinostat
Sponsor: National Cancer Institute (NCI)
Completed - verified February 2007
Condition: Cancer
Interventions: Drug: dexamethasone; Drug: ondansetron; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Gastric Cancer
Interventions: Drug: bryostatin 1; Drug: cisplatin
Sponsors: USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified September 2003
Conditions: Esophageal Cancer; Gastric Cancer
Intervention: Drug: irinotecan hydrochloride
Sponsors: University of California, Los Angeles; National Cancer Institute (NCI); Pharmacia and Upjohn
Completed - verified February 2010
All Categories ... Medical Conditions » ... Cancers » ... Stomach Cancer 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
